Kura Oncology, Inc. (KURA)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 15.3M | 20.8M | 17.3M | 18.3M |
| Gross Profit | 18.0M | |||
| Operating Income | -72.7M | -80.0M | -86.3M | -78.8M |
| Net Income | -66.1M | -74.1M | -81.0M | -73.3M |
| Diluted EPS | $-0.75 | $-0.85 | $-0.92 | $-0.83 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 53.9M | 67.5M |
| Gross Profit | 0.00 | 53.9M | 67.4M | |
| Operating Income | -139.9M | -165.8M | -193.2M | -303.6M |
| Net Income | -135.8M | -152.6M | -174.0M | -278.7M |
| Diluted EPS | $-2.03 | $-2.08 | $-2.02 | $-3.18 |